- Home
- CHE vs RGEN Comparison
CHE vs RGEN Comparison
Compare CHE & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHE
- RGEN
- Stock Information
- Founded
- CHE 1970
- RGEN 1981
- Country
- CHE United States
- RGEN United States
- Employees
- CHE N/A
- RGEN N/A
- Industry
- CHE Medical/Nursing Services
- RGEN Medical/Dental Instruments
- Sector
- CHE Health Care
- RGEN Health Care
- Exchange
- CHE Nasdaq
- RGEN Nasdaq
- Market Cap
- CHE 8.7B
- RGEN 8.2B
- IPO Year
- CHE N/A
- RGEN N/A
- Fundamental
- Price
- CHE $577.91
- RGEN $136.22
- Analyst Decision
- CHE Buy
- RGEN Buy
- Analyst Count
- CHE 2
- RGEN 10
- Target Price
- CHE $673.50
- RGEN $188.38
- AVG Volume (30 Days)
- CHE 55.6K
- RGEN 772.8K
- Earning Date
- CHE 10-29-2024
- RGEN 10-29-2024
- Dividend Yield
- CHE 0.35%
- RGEN N/A
- EPS Growth
- CHE 31.50
- RGEN N/A
- EPS
- CHE 19.72
- RGEN N/A
- Revenue
- CHE $2,335,557,000.00
- RGEN $602,354,000.00
- Revenue This Year
- CHE $8.90
- RGEN $0.08
- Revenue Next Year
- CHE $7.70
- RGEN $12.97
- P/E Ratio
- CHE $29.36
- RGEN N/A
- Revenue Growth
- CHE 6.79
- RGEN N/A
- 52 Week Low
- CHE $497.37
- RGEN $110.45
- 52 Week High
- CHE $654.62
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- CHE 54.59
- RGEN 37.10
- Support Level
- CHE $558.41
- RGEN $138.80
- Resistance Level
- CHE $576.28
- RGEN $150.72
- Average True Range (ATR)
- CHE 8.36
- RGEN 5.27
- MACD
- CHE -0.70
- RGEN -1.23
- Stochastic Oscillator
- CHE 61.51
- RGEN 1.94
About CHE Chemed Corp
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.